Shattuck Labs (STTK) EBITDA Yield: History & Chart

Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.

The EBITDA yield is N/A as of 2026-10-06T21:48:17.806Z.

Stored calculation inputs

Calculation as of: 2026-10-06T21:48:17.806Z.

Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.

TTM operating EBITDA · period ending 2026-06-30: -51,673,000
Quote market capitalization: 529,582,205
Total debt · period ending 2026-06-30: 2,674,000
Cash · period ending 2026-06-30: 63,299,000

FMP input reference: 35a271d61501d442ff1d5238fcf80e89d6bdfa5e87b371fe53e06a7cba571f48

EV/EBITDA|Earnings Yield|OCF Yield|FCF Yield|All Metrics

STTK EBITDA Yield Metrics

EBITDA YIELD

N/A

STTK Competitors' EBITDA Yield

STTK

Shattuck Labs, Inc.

Current

Market Cap

$529.58M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NVCT

Nuvectis Pharma, Inc.

vs STTK

Market Cap

$531.52M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

DCTH

Delcath Systems, Inc.

vs STTK

Market Cap

$531.98M

EBITDA Yield

N/A

TTM Avg

1.23%

3Y Avg

1.23%

5Y Avg

1.23%

MNPR

Monopar Therapeutics Inc.

vs STTK

Market Cap

$533.04M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

IMMX

Immix Biopharma, Inc.

vs STTK

Market Cap

$524.43M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

PROK

ProKidney Corp.

vs STTK

Market Cap

$538.01M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ALT

Altimmune, Inc.

vs STTK

Market Cap

$519.25M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ACRS

Aclaris Therapeutics, Inc.

vs STTK

Market Cap

$516.76M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

PHAT

Phathom Pharmaceuticals, Inc.

vs STTK

Market Cap

$548.51M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

MASS

908 Devices Inc.

vs STTK

Market Cap

$505.87M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EBITDA YIELD	TTM	3Y	5Y
Shattuck Labs, Inc. (STTK)	$529.58M	N/A	N/A	N/A	N/A
Nuvectis Pharma, Inc. (NVCT)vs ›	$531.52M	N/A	N/A	N/A	N/A
Delcath Systems, Inc. (DCTH)vs ›	$531.98M	N/A	1.23%	1.23%	1.23%
Monopar Therapeutics Inc. (MNPR)vs ›	$533.04M	N/A	N/A	N/A	N/A
Immix Biopharma, Inc. (IMMX)vs ›	$524.43M	N/A	N/A	N/A	N/A
ProKidney Corp. (PROK)vs ›	$538.01M	N/A	N/A	N/A	N/A
Altimmune, Inc. (ALT)vs ›	$519.25M	N/A	N/A	N/A	N/A
Aclaris Therapeutics, Inc. (ACRS)vs ›	$516.76M	N/A	N/A	N/A	N/A
Phathom Pharmaceuticals, Inc. (PHAT)vs ›	$548.51M	N/A	N/A	N/A	N/A
908 Devices Inc. (MASS)vs ›	$505.87M	N/A	N/A	N/A	N/A

EBITDA Yield Formula & Definition

EBITDA Yield = TTM EBITDA / Enterprise Value

EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EBITDA Yield: N/A

STTK EBITDA Yield Metrics

STTK Competitors' EBITDA Yield

EBITDA Yield Formula & Definition

Related Metrics